Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xvivo Perfusion ABXVIPF 86 Cyclically Adjusted Price-to-FCF is 136.11 as of Aug. 17, 2026, which is 68% below its 10-year median of 421.09. GuruFocus rates XVIPF with a GF Score™ of 86/100 and a GF Value™ of $44.46 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 261 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 94.64% on this metric.
The historical rank and industry rank for Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
XVIPF'
s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 137.77 Med: 421.09 Max: 728.38
Current: 180.4
During the past years, Xvivo Perfusion AB's highest Cyclically Adjusted Price-to-FCF was 728.38. The lowest was 137.77. And the median was 421.09.
XVIPF's Cyclically Adjusted Price-to-FCF is ranked worse than 94.64% of 261
companies
in the Medical Devices & Instruments industry
Industry Median: 33.1
vs XVIPF: 180.40
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Xvivo Perfusion AB's adjusted free cash flow per share data for the three months ended in Jun. 2026 was $0.212. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.18 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Xvivo Perfusion AB (OTCPK:XVIPF) Cyclically Adjusted Price-to-FCF Explanation
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Xvivo Perfusion AB Cyclically Adjusted Price-to-FCF Related Terms
Xvivo Perfusion AB Cyclically Adjusted Price-to-FCF Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB Cyclically Adjusted Price-to-FCF Chart
XVIPF vs ABT, SYK, MDT: Cyclically Adjusted Price-to-FCF Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF falls into.
Xvivo Perfusion AB Cyclically Adjusted Price-to-FCF Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted Price-to-FCF of 136.11 mean?
Xvivo Perfusion AB (XVIPF) has a Cyclically Adjusted Price-to-FCF of 136.11 as of Aug. 17, 2026. Cyclically Adjusted Price-to-FCF Ratio is the ratio of share price to a company's inflation-adjusted FCF per share over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors. This is 68% below median its historical median of 421.09. Over the past decade, Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF has ranged from 137.77 to 728.38. According to the industry distribution chart, Xvivo Perfusion AB ranks #247 out of 261 companies in the Medical Devices & Instruments industry, placing it in the top 94.6%.
Is Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF too high?
Xvivo Perfusion AB's current Cyclically Adjusted Price-to-FCF of 136.11 is 68% below median its 10-year median of 421.09. Over the past 10 years, this metric has ranged from a low of 137.77 to a high of 728.38. The Medical Devices & Instruments industry median Cyclically Adjusted Price-to-FCF is 33.10. Xvivo Perfusion AB's value of 136.11 is 311.2% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #247 out of 261 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #247 out of 261 companies for Cyclically Adjusted Price-to-FCF. This places Xvivo Perfusion AB in the lower half of its industry. The industry median Cyclically Adjusted Price-to-FCF is 33.10. Xvivo Perfusion AB's value of 136.11 is 311.2% above this benchmark. Historically, Xvivo Perfusion AB's own Cyclically Adjusted Price-to-FCF has ranged from 137.77 to 728.38 over the past decade. While the company's 10-year median is 421.09 vs. the industry median of 33.10, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Price-to-FCF for a Medical Devices & Instruments company?
The median Cyclically Adjusted Price-to-FCF among Medical Devices & Instruments companies is 33.10, based on 261 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted Price-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted Price-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Cyclically Adjusted Price-to-FCF of 136.11 is 311.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Price-to-FCF mean?
A high Cyclically Adjusted Price-to-FCF can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted Price-to-FCF Ratio is the ratio of share price to a company's inflation-adjusted FCF per share over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted Price-to-FCF is 33.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Cyclically Adjusted Price-to-FCF is 136.11, which is 68% below median its own 10-year median of 421.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $44.46, compared to a current price of $24.50 — trading 44.9% below its estimated fair value. The current Cyclically Adjusted Price-to-FCF is 136.11, which is 68% below median its 10-year median of 421.09 and 311.2% above the Medical Devices & Instruments industry median of 33.10. Xvivo Perfusion AB's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Price-to-FCF calculated?
Cyclically Adjusted Price-to-FCF is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Cyclically Adjusted Price-to-FCF is 136.11 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $24.50 is trading 44.9% below its estimated GF Value™ of $44.46.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Cyclically Adjusted Price-to-FCF: 136.11 (68% below median its 10-year median of 421.09)
GF Value™: $44.46 vs. price of $24.50 (44.9% below fair value)
Industry Position: 311.2% above the Medical Devices & Instruments median (#247 of 261)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
86GF Score
Get the complete analysis for XVIPF
Cyclically Adjusted Price-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
